Luo Jianhua, Li Qiaoqiao, Pan Junsu, Li Longxiang, Fang Liangjie, Zhang Ying
Department of Respiratory, Taizhou Municipal Hospital, Taizhou, Zhejiang, PR China.
Department of Respiratory, The First Affiliated Hospital, Zhejiang University, Hangzhou, PR China.
J Cancer Res Ther. 2018;14(4):860-863. doi: 10.4103/jcrt.JCRT_733_17.
This study was aimed to explore the expression level of long noncoding RNA H19 in the plasma of patients with nonsmall cell lung cancer (NSCLC) and its clinical significance.
A total of 66 NSCLC patients (case group) and 31 patients with benign lung disease (control group) admitted from February 2015 to February 2017 were included in this study. Real-time polymerase chain reaction assay was applied to examine the relative expression level of long noncoding RNA H19 in the plasma of the two groups. The relationship between H19 expression and clinical, pathological features was explored. Receiver-operating characteristic (ROC) curve was applied to evaluate the clinical value of plasma H19 as a tumor marker in the auxiliary diagnosis of NSCLC.
The relative expression levels of plasma H19 inpatients from NSCLC group and benign lung disease group were 5.62 ± 2.02 (ΔCt) and 7.74 ± 2.75 (ΔCt), respectively. The NSCLC group presented with significantly higher levels than that of the benign disease group (P < 0.05). According to the median of relative expression level of 5.54, the plasma H19 of NSCLC patients was classified into low expression group ≥5.54 (n = 34) and high expression group <5.52 (n = 32). The relationship between the patients' clinical, pathological features, and the expression level of H19 was analyzed. The expression of H19 was not significantly correlated with the gender, age, clinical staging, tumor diameter, and pathological type of the patients (P > 0.05). With the serum H19 as a diagnosis reference, the diagnostic sensitivity of NSCLC was 67.74%, and the specificity was 63.08%. The area under the ROC curve was 0.73, and the diagnostic cutoff value was 6.62.
Plasma level of H19 in NSCLC patients was significantly increased, which could be applied as a serological marker for the auxiliary diagnosis of NSCLC.
本研究旨在探讨长链非编码RNA H19在非小细胞肺癌（NSCLC）患者血浆中的表达水平及其临床意义。
本研究纳入了2015年2月至2017年2月收治的66例NSCLC患者（病例组）和31例良性肺疾病患者（对照组）。采用实时聚合酶链反应检测两组患者血浆中长链非编码RNA H19的相对表达水平。探讨H19表达与临床、病理特征之间的关系。应用受试者工作特征（ROC）曲线评估血浆H19作为肿瘤标志物在NSCLC辅助诊断中的临床价值。
NSCLC组和良性肺疾病组患者血浆H19的相对表达水平分别为5.62±2.02（ΔCt）和7.74±2.75（ΔCt）。NSCLC组的水平显著高于良性疾病组（P<0.05）。根据相对表达水平中位数5.54，将NSCLC患者的血浆H19分为低表达组≥5.54（n=34）和高表达组<5.52（n=32）。分析患者临床、病理特征与H19表达水平之间的关系。H19的表达与患者的性别、年龄、临床分期、肿瘤直径和病理类型无显著相关性（P>0.05）。以血清H19作为诊断参考，NSCLC的诊断敏感性为67.74%，特异性为63.08%。ROC曲线下面积为0.73，诊断临界值为6.62。
NSCLC患者血浆中H19水平显著升高，可作为NSCLC辅助诊断的血清学标志物。
